University of Dundee

Biological Chemistry and Drug Discovery

Short Code: 

EN & MN Lindsay Scholarship: Computer-aided drug discovery (CADD) methodologies for the identification and optimisation of bioactive compounds

We invite applications to this project for a fully funded four-year EN & MN Lindsay Endowed PhD studentship. The student will be based in the School of Life Sciences, one of the UK’s flagship institutions for biological research.

Molecular recognition, the specific interaction between two or more molecules through noncovalent bonding, plays an important role in biological systems and is fundamental for the development of small molecules capable of modulating biochemical processes to treat diseases.

Drug Discovery Award for Alessio Ciulli

Professor Alessio Ciulli has been awarded a European Federation for Medicinal Chemistry and Chemical Biology Awards 2022. He has been named the winner of the 2022 Prous Institute - Overton and Meyer Award for New Technologies in Drug Discovery. This award has been in recognition of his “pioneering work in the field of proteolysis-targeting chimera (PROTAC) technology for drug-induced targeted protein degradation.

Dundee ranked top University for Biological Sciences in REF 2021

The results of the 2021 Research Excellence Framework (REF) were announced today. Dundee is the top-ranking University for Biological Sciences research, a position we have maintained since the last REF exercise in 2014. The REF2021 assessment has scored SLS as having a total of 71% of its activities being ‘world leading’ (4*) and 28% of its activities being ‘internationally excellent’ (3*).

Parasite gene-editing technology for profiling drug-resistance mutations

A team from the Wellcome Centre for Anti-Infectives Research (WCAIR) at the University of Dundee has developed a new parasite gene-editing technology. This method, known as oligo-targeting, involves delivering short DNA fragments to parasites using a pulse of electricity. The DNA, including the desired edits, is then incorporated into the genomes of cells that are in the process of replicating their DNA. The approach is fast, simple, precise, and inexpensive.

Amphista announces collaborations potentially worth $2 billion

University of Dundee spinout Amphista Therapeutics will work with global biopharmaceutical companies as part of strategic collaborations potentially worth more than $2 billion.

As part of separate partnerships, Amphista will collaborate with Merck Healthcare and Bristol Myers Squibb to leverage the company’s targeted protein degradation (TPD) technology and generate therapeutics in multiple disease areas.


The School of Life Sciences at the University of Dundee is a world-class academic institution with a reputation for the excellence of its research, its high qu